We use murine models of allergic airways disease to better understand how innate and adaptive immunity coordinate to promote type 2 inflammation in the lung. We are currently examining how innate cells in the lung, activated by IL-33 in adult mice, or respiratory syncytial virus (RSV) in young mice, promote type 2 inflammation and Th2 adaptive immunity. One focus of our work is to better understand how STAT6 activation in eosinophils promotes their activity. As part of our program to understand the link between innate and Th2 adaptive immunity in the lung, we are characterizing activity of an immunomodulatory peptide we developed (STAT6-IP). We have also developed murine models of atopic dermatitis to extend these studies. Finally, we are characterizing how sex and sex hormones influence each of these outcomes.
View Elizabeth Fixman’s posts and news:
Scientists discover peptide that could reduce the incidence of RSV-related asthma.
RI-MUHC, Block E
1001 Decarie Blvd.
Montreal QC H4A 3J1
Tel: 514-934-1934 Ext. 76366 (lab)
Tel: 514-934-1934 Ext. 76242 (office)
Tel: 514-934-1934 Ext. 76172 (admin)
E-Mail: elizabeth.fixman [at] mcgill.ca
Education & Training
BSc (Chem/Biochem) Colorado State U (1986)
PhD (Pharmacology) Johns Hopkins (1992)
Adv Topics in Respiration, EXMD 508